A cost-utility analysis of interferon beta for multiple sclerosis

Health Technol Assess. 1998;2(4):iii-54.
No abstract available

MeSH terms

  • Adjuvants, Immunologic / economics*
  • Adjuvants, Immunologic / therapeutic use
  • Adult
  • Aged
  • Cost-Benefit Analysis
  • Decision Support Techniques
  • Drug Costs*
  • Female
  • Health Status
  • Humans
  • Interferon-beta / economics*
  • Interferon-beta / therapeutic use
  • Male
  • Medical Records
  • Middle Aged
  • Models, Econometric
  • Multiple Sclerosis / drug therapy*
  • Outcome Assessment, Health Care
  • Quality-Adjusted Life Years
  • United Kingdom

Substances

  • Adjuvants, Immunologic
  • Interferon-beta